Asabys Partners close €180m Sabadell Asabys II Fund
Asabys Partners have announced the closing of a new oversubscribed fund aimed at investing in 12-15 companies across all areas of pharma biotech.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1300 entries already.
Entries by Thomas Gabrielczyk
Genespire raises US$52m in Series B round
/in News/by Thomas GabrielczykItalian SR-Tiget spin out Genespire srl will use the proceeds of a €46.6m (US$52m) Series B financing to advance its paediatric in-vivo gene therapy for the rare metabolic disorder Methylmalonic Acidemia (MMA) to Phase I/II testing.
AMR Accelerator urges long-term funding
/in News/by Thomas GabrielczykAntimicrobial resistance (AMR) poses a huge threat to the prevention and treatment of a growing number of infections caused by bacteria, parasites, viruses, and fungi. A public-private partnership involving nine European projects and 98 organisations is now calling for long-term investment to maintain Europe’s ability to research and develop new antibiotics.
Vicebio Ltd cashes in US$100m in Series B financing
/in News/by Thomas GabrielczykLondon-based Vicebio Ltd has announced a US$100m Series B financing that will support Phase I testing of its bivalent RSV vaccine candidate VXB-241 and pushing development of another pipeline programme.
French Brenus AS closes US$25m financing
/in News/by Thomas GabrielczykFrench Brenus Pharma SA has raised €22.2m (US$25m) to accelerate clinical trials of two precision cancer vaccines derived from tumour cell banks representing more than 200 tumour antigens.
Von der Leyen names new EU Commissioners
/in News/by Thomas GabrielczykEuropean Commission President Ursula von der Leyen has revealed her nominees for new commissioners to lead the bloc for the next term from 2024 to 2029.
ImmunOs Therapeutics AG raises US$11m in Series C financing
/in News/by Thomas GabrielczykSwiss cancer and auto-immunity specialist ImmunOs Therapeutics AG has closed a Series C financing round of US$11m led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures.
Richter-Helm Biologics triples production capacity
/in News/by Thomas GabrielczykAfter three and a half years of construction, the CDMO Richter Biologics has inaugurated its new multipurpose production facility that triples the CDMO’s capacity for the bacterial production of pDNA, vaccines, nanobodies and recombinant proteins.
Phoremost reports Series B extension
/in News/by Thomas GabrielczykBritish protein degrader specialist PhoreMost Ltd has extended its €33m Series B financing to $50M and plans to advance its oncology and inflammation degrader programmes.
Funding for green insecticides
/in News/by Thomas GabrielczykAgri-biotech SOLASTA Bio Ltd. has raised US$14m in a Series A funding round led by Forbion. With the money, the UK company will advance its first-of-a kind peptide-based bioinsecticide.